IRB #

IRB00011766

Title

A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined with Induction Chemotherapy in Acute Myeloid Leukemia in Patients who Exhibit in vitro Kinase Inhibitor Sensitivity

Principal Investigator

Stephen Spurgeon

Study Purpose

The purpose of this research study is to test the safety of adding a targeted study drug after receiving the standard 7+3 chemotherapy treatment for AML. The pathways responsible for activating the growth of leukemia cells can be unique to each patient and can change during the course of the disease. The lab test developed by the investigators at OHSU will help screen your blood or bone marrow to find out if your cancer may be sensitive to a specific study drug. This is called “targeted therapy”. The reason for doing this research study is to see if the new investigational screening lab test can help provide individualized treatment for patients with leukemia. This study will allow the researchers to learn more about how AML responds to treatment.

Medical Condition(s)

Newly diagnosed acute myeloid leukemia (AML).

Eligibility Criteria

Newly diagnosed acute myeloid leukemia (AML) and physician recommendation based on study inclusion and exclusion criteria.

Age Range

21 - No Upper Age Limit

Healthy Volunteers Needed

No

Duration of Participation

Treatment period of 1 month. Follow-up for 1 year.

Minors Included

No

Contact

Tara Macey, PhD
503-494-1976

Sponsor

Stephen Spurgeon, MD

Recruitment End

04/17/2050

Compensation Provided

No


Go Back